The global VALOR trial enrolled 241 adults with dermatomyositis across 90 clinical sites and assessed two doses of brepocitinib compared with placebo. The primary outcome was change in Total Improvement Score (TIS), a validated composite measure encompassing six domains of myositis disease activity. At 52 weeks, patients receiving brepocitinib 30 mg showed a statistically significant and clinically robust improvement, achieving a mean TIS increase more than 15 points greater than placebo.

Clinical benefit with brepocitinib emerged rapidly. Differences between the active treatment and placebo groups were observed as early as four weeks and were maintained throughout the one‑year double‑blind period. In addition to meeting the primary endpoint, the 30 mg dose met all nine key secondary endpoints, which included measures of muscle strength, skin involvement, physical function, and corticosteroid reduction.

Steroid‑Sparing Potential and Broad Efficacy

One of the most notable findings from VALOR was brepocitinib’s steroid‑sparing effect. Nearly twice as many patients in the 30 mg group were able to meaningfully taper background corticosteroids compared with placebo. More than half of treated patients achieved a substantial clinical response—defined as reaching a TIS of at least 40—while also reducing prednisone‑equivalent doses to 2.5 mg per day or less. This dual benefit is particularly relevant given the long‑term toxicity associated with chronic steroid use in dermatomyositis.

The trial population reflected the heterogeneity of real‑world dermatomyositis, including individuals with prior malignancy and patients with multiple cardiovascular risk factors. According to the investigators, this broad inclusion enhances the generalizability of the findings and supports brepocitinib’s potential role across a wide disease spectrum.

Safety Findings and Contextual Risk

Serious infections occurred more frequently among patients receiving brepocitinib 30 mg than placebo, although these events generally resolved with standard medical treatment and rarely required permanent discontinuation of therapy. Importantly, adverse events leading to treatment cessation were more common in the placebo group.

Rates of malignancy, cardiovascular events, and thromboembolic complications were also higher among placebo‑treated patients. Trial authors suggested that this imbalance likely reflects the underlying risks of dermatomyositis itself, as well as the cumulative effects of traditional immunosuppressive therapies, particularly prolonged systemic corticosteroid exposure.

Across the broader clinical development program, brepocitinib has been studied in more than 2,000 participants. The overall safety profile observed to date appears consistent with that of currently approved JAK and TYK2 pathway inhibitors.

Skin‑Focused and Patient‑Reported Benefits

Additional analyses presented at the 2026 American Academy of Dermatology Annual Meeting provided further insight into the drug’s effects on skin manifestations and quality of life. Patients treated with brepocitinib 30 mg experienced rapid relief from itch, with a significantly higher proportion achieving near‑complete resolution by week four compared with placebo.

Improvements were also seen in skin‑related quality‑of‑life scores, as measured by Skindex‑16, and these benefits persisted through week 52. Among patients with moderate‑to‑severe skin disease at baseline—a subgroup often resistant to standard therapies—brepocitinib was associated with markedly higher rates of functional skin remission.

Regulatory Outlook

Based on the VALOR data package, the U.S. Food and Drug Administration has granted Priority Review to brepocitinib’s New Drug Application. A regulatory decision is expected in the third quarter of 2026.

Experts involved in the study have suggested that, if approved, brepocitinib could represent a paradigm shift in dermatomyositis management by offering sustained disease control while reducing long‑term corticosteroid exposure. The publication of the VALOR trial in a leading medical journal underscores the potential clinical importance of these findings for patients and clinicians alike.